Clinical Trials Browser

Bone Marrow Diseases, Hematologic Diseases, Leukemia, Leukemia, Myeloid, Myelodysplastic Syndromes, Preleukemia, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic

NCT03063944 2025-05-15

STAT Inhibitor OPB-111077, Decitabine and Venetoclax in Treating Patients With Acute Myeloid Leukemia That Is Refractory, Relapsed or Newly Diagnosed and Ineligible for Intensive Chemotherapy

Phase 1 Completed

37 enrolled

Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT03017131 2025-03-28

Genetically Modified T Cells and Decitabine in Treating Patients With Recurrent or Refractory Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Phase 1 Active not recruiting

9 enrolled

Gynecologic

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT04277442 2025-03-25

Testing Nivolumab in Combination With Decitabine and Venetoclax in Patients With Newly Diagnosed TP53 Gene Mutated Acute Myeloid Leukemia

Phase 1 Completed

1 enrolled 8 charts

Other hematologic neoplasm

Leukemia, Myeloid, Acute

Clinical Trials

Bortezomib, Sorafenib Tosylate, and Decitabine in Treating Patients With Acute Myeloid Leukemia

Testing a New Chemotherapy Drug, KRT-232 (AMG-232) in Combination With Decitabine and Venetoclax in Patients With Acute Myeloid Leukemia

CELESTIAL-MDS

Pembrolizumab and Decitabine With or Without Venetoclax in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome That Is Newly-Diagnosed, Recurrent, or Refractory

Study of Venetoclax in Combination With Decitabine in Subjects With Acute Myeloid Leukemia

Trial of Novel Anti-leukemia Agents in Flu/Mel RIC Transplant for Myeloid Malignancies

FHD-286

DEC-205/NY-ESO-1 Fusion Protein CDX-1401, Poly ICLC, Decitabine, and Nivolumab in Treating Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia

Talazoparib for Cohesin-Mutated AML and MDS With Excess Blasts

High-dose Ascorbate (HDA) in Combination With Standard of Care Azacitidine and Venetoclax in Acute Myeloid Leukemia (AML)

Combination Navitoclax, Venetoclax and Decitabine for Advanced Myeloid Neoplasms

Adoptive T Cell Therapy With DC/AML Fusion Vaccine Plus Decitabine and Venetoclax in AML

Decitabine in Combination With Standard of Care Therapy for the Treatment of Surgically Resectable HPV-Negative Head and Neck Cancer

Dose-Escalation Study of E7727, an Oral Cytidine Deaminase Inhibitor With Oral Decitabine in Subjects With Solid Tumors

Tegavivint for the Treatment of Relapsed or Refractory Leukemia

Avapritinib With Decitabine in Patients With SM-AHN

Navitoclax in Relapsed or Refractory High-Risk Myelodysplastic Syndrome

Palbociclib and Sorafenib, Decitabine, or Dexamethasone in Treating Patients With Recurrent or Refractory Leukemia

Epigenetic Reprogramming in Relapse/Refractory AML

Decitabine and Nivolumab in Participants With Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck

Oral Decitabine (ASTX727) and Durvalumab in Recurrent and/or Metastatic Head and Neck Cancer Patients

Study of Pembrolizumab Combined With Decitabine and Pralatrexate in PTCL and CTCL

Inqovi Maintenance Therapy in Myeloid Neoplasms

FHD-286 as Monotherapy or Combination Therapy in Subjects With Advanced Hematologic Malignancies

Pevonedistat and Decitabine in Treating Patients With High Risk Acute Myeloid Leukemia

Navitoclax, Venetoclax, and Decitabine for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia Previously Treated With Venetoclax

A Phase 1 Study With LYT-200 in Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML), or With Relapsed/Refractory, High-risk Myelodysplastic Syndrome (MDS)

Study of PDR001 and/or MBG453 in Combination With Decitabine in Patients With AML or High Risk MDS

STAT Inhibitor OPB-111077, Decitabine and Venetoclax in Treating Patients With Acute Myeloid Leukemia That Is Refractory, Relapsed or Newly Diagnosed and Ineligible for Intensive Chemotherapy

Genetically Modified T Cells and Decitabine in Treating Patients With Recurrent or Refractory Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Testing Nivolumab in Combination With Decitabine and Venetoclax in Patients With Newly Diagnosed TP53 Gene Mutated Acute Myeloid Leukemia